SYNLOGIC, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
SYNLOGIC, INC. (SYBX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-03-29
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-03-31 was $1.27M, a 15.33% decline year-over-year.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $1.27M, a 95.55% decline from fiscal 2020.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $28.52M, a 81.89% decline from fiscal 2019.
- SYNLOGIC, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $157.47M, a 72.39% increase from fiscal 2018.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | $1.27M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $1.27M 10-Q · filed 2022-11-10 | $13.04M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.27M 10-Q · filed 2022-08-11 | $13.04M derived: sum of 3 quarters · filed 2022-08-11 | $14.54M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.27M 10-Q · filed 2022-05-12 | $13.04M derived: sum of 2 quarters · filed 2022-05-12 | $14.54M derived: sum of 3 quarters · filed 2022-05-12 | $28.29M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $13.27M derived: sum of 2 quarters · filed 2022-03-17 | $27.02M derived: sum of 3 quarters · filed 2022-03-17 | $28.52M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $15.25M derived: sum of 2 quarters · filed 2021-11-10 | $16.75M 10-Q · filed 2021-11-10 | $43.07M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $13.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $15.25M 10-Q · filed 2021-08-12 | $41.57M derived: sum of 3 quarters · filed 2021-08-12 | $83.22M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $1.50M 10-Q · filed 2021-05-13 | $18.85M 10-Q · filed 2020-05-08 | $27.82M derived: sum of 2 quarters · filed 2021-05-13 | $69.47M derived: sum of 3 quarters · filed 2021-05-13 | $101.68M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $67.97M derived: sum of 2 quarters · filed 2020-03-12 | $100.18M derived: sum of 3 quarters · filed 2020-03-12 | $157.47M 10-K · filed 2020-03-12 | |
| 2019-09-30 | $41.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $73.86M derived: sum of 2 quarters · filed 2019-11-12 | $131.15M 10-Q · filed 2019-11-12 | $163.76M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2019-06-30 | $32.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $89.50M 10-Q · filed 2019-08-08 | $122.11M derived: sum of 3 quarters · filed 2020-05-08 | $153.39M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2019-03-31 | $57.28M 10-Q · filed 2020-05-08 | $89.89M derived: sum of 2 quarters · filed 2020-05-08 | $121.18M derived: sum of 3 quarters · filed 2020-05-08 | $143.62M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $63.90M derived: sum of 2 quarters · filed 2020-03-12 | $86.34M derived: sum of 3 quarters · filed 2020-03-12 | $91.34M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $31.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $53.73M derived: sum of 2 quarters · filed 2019-11-12 | $58.73M 10-Q · filed 2019-11-12 | $76.13M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $22.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $27.45M 10-Q · filed 2019-08-08 | $44.84M derived: sum of 3 quarters · filed 2019-08-08 | $11.34M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $5.00M 10-Q · filed 2019-05-09 | $22.40M derived: sum of 2 quarters · filed 2019-05-09 | -$11.10M derived: sum of 3 quarters · filed 2019-05-09 | $12.27M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$16.10M derived: sum of 2 quarters · filed 2019-03-12 | $7.27M derived: sum of 3 quarters · filed 2019-03-12 | $22.85M 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$33.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$10.13M derived: sum of 2 quarters · filed 2018-11-13 | $5.45M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $23.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $38.95M 10-Q · filed 2017-08-04 | |||
| 2017-03-31 | $15.58M 10-Q · filed 2017-05-09 | ||||
| 2016-12-31 | $58.78M 10-K · filed 2017-03-15 | ||||
| 2016-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $9.00M 10-Q · filed 2017-08-04 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |